Tuesday, 20 Mar 2018

You are here

Gout Crystal Deposition is Deeper than its Measures

Dalbeth and colleagues have published that among gout patients without palpable tophic and despite long term allopurinol, nearly half have monosodium urate (MSU) as detected by Dual-energy CT (DECT).  The total body urate deposition is even greater in those with higher sUA and evidence of severe disease. 

They enrolled 152 gout patients from New Zealand and USA who were receiving allopurinol ≥300 mg/day for a mean of 5.1 years. MSU crystal deposition was assessed b DECT in the hands/wrists, feet/ankles/Achilles and knees and correlated with sUA levels and gout characteristics.

  • Among allopurinol treated patients, 69.1% had crystal deposition on DECT, with a median total crystal volume of 0.16 cm3.
  • Crystal deposition was found in 46.9% of patients with sUA <6.0 mg/dL and no palpable tophi
  • Crystal deposition was found in 90.0% among those with sUA ≥6.0 mg/dL and tophi.
  • Total volume of crystal deposition was positively associated with sUA ≥6.0 mg/dL, gout flares, tophi and the patients global disease activity scores.

These data are sobering, given the fact that only 30-45% of treated gouty patients will achieve a treat-to-target goal of sUA <6.0 mg/dl. Nearly half of the patients who achieve that goal in this cohort study still had tissue MSU crystal deposition.  

Gout runs deeper than the tophi and is more sinister than the serum urate level measured.

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Does Dose Escalation Help in Gout?

Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.

CARES Study- More CV Deaths with Febuxostat

The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat. (Citation source bit.ly/2HtUEaz)

Probenecid Benefits Heart Failure

In animal studies, probenecid was shown to have positive inotropic effects on the cardiomyocyte mediated by transient receptor potential vanilloid 2 activation. This concept was further studied in 20 patients with heart failure with reduced ejection fraction where probenecid was shown to improve cardiac function after just one week of probenecid treatment.

T2T Improves Primary Care Gout Management

Researchers from Geisinger Medical center tested a pilot primary care gout management improvement intervention, and demonstrated significantly improved primary care gout management metrics when a treat to target approach was implemented. 

New BSR 2017 Gout Guidelines (Best of 2017)

The British Society for Rheumatology/British Health Professionals in Rheumatology first published a guideline for the management of gout in 2007. They have just updated and published their new guideline, largely because of new therapies, an increasing incidence of gout, low penetrance of urate lowering therapies, and the inability to achieve a target serum uric acid level.